Humidified Warmed CO₂ Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review

Alaa M. M. El-Betany 1*, Enas M. Behiry 2, Mark Gumbleton 1* and Keith G. Harding 3*

1 School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom, 2 School of Medicine, Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, 3 Wound Healing Research Unit, Welsh Wound Innovation Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom

The coronavirus disease (COVID-19) outbreak has presented enormous challenges for healthcare, societal, and economic systems worldwide. There is an urgent global need for a universal vaccine to cover all SARS-CoV-2 mutant strains to stop the current COVID-19 pandemic and the threat of an inevitable second wave of coronavirus. Carbon dioxide is safe and superior antimicrobial, which suggests it should be effective against coronaviruses and mutants thereof. Depending on the therapeutic regime, CO₂ could also ameliorate other COVID-19 symptoms as it has also been reported to have antioxidant, anti-inflammation, anti-cytokine effects, and to stimulate the human immune system. Moreover, CO₂ has beneficial effects on respiratory physiology, cardiovascular health, and human nervous systems. This article reviews the rationale of early treatment by inhaling safe doses of warmed humidified CO₂ gas, either alone or as a carrier gas to deliver other inhaled drugs may help save lives by suppressing SARS-CoV-2 infections and excessive inflammatory responses. We suggest testing this somewhat counter-intuitive, but low tech and safe intervention for its suitability as a preventive measure and treatment against COVID-19. Overall, development and evaluation of this therapy now may provide a safe and economical tool for use not only during the current pandemic but also for any future outbreaks of respiratory diseases and related conditions.

Keywords: anti-COVID-19, antiviral, anti-cytokine storm, improve COVID-19 symptoms, carrier gas composition, enhancer antiviral, protect and improve organs function, suppress COVID-19 pandemic

BACKGROUND

The coronavirus disease (COVID-19) outbreak has presented enormous challenges for healthcare systems worldwide and caused terrible societal and economic impacts. There is also an urgent need to address health inequality in treating the current COVID-19 pandemic. Even now, scientists are racing to unravel sometimes conflicting information to understand the source, diagnose, and find effective treatments for SARS-CoV-2, and to conduct clinical trials of antiviral drugs and vaccines. Other COVID-19 mysteries include the appearance of new symptoms, the relation of silent hypoxia and sudden deaths, spikes insignificant vessel blockages, and increased risks of clotting (1). The
El-Betany et al. Carbon Dioxide Therapy as a Promising Anti-COVID-19

GRAPHICAL ABSTRACT | Precise control of the unique properties and intervention parameters of warmed humidified CO₂ gas make it a promising anti-COVID-19 therapy for mitigation and suppression of SARS-CoV-2 infection.

virus is now known to be able to target a wide variety of cells throughout the human body through ACE2 and TMPRSS2 receptors (2) and is believed to have caused a spike in a rare syndrome: “multi-system inflammatory state requiring intensive care” in children. Furthermore, the mode of transmission and the extent of environmental contamination is yet unknown. While the virus may not technically be airborne, it is definitely borne in the air as aerosols (3).

One of the most critical unanswered questions is why some COVID-19 patients develop severe disease, while others do not? Does the answer hidden in the origin and continuing evolution of SARS-CoV-2 virus mutation into mild and wild different strains (4)? Alternatively, does the answer depend on the two phases of the individual human body immune responses; a protective phase and a damaging phase due to inflammation-cytokine storms (5)? Other questions include whether bacterial co-infections such as bacterial pneumonia and sepsis with antibiotic resistance lead to increased COVID-19 disease severity and mortality (6) and how long it will take to create an effective vaccine. Potential SARS-CoV-2 vaccines have a variety of approaches that depend on viral life cycles (7), and it is estimated that a vaccine will either arrive in 1 or 2 years or will never arrive at all. Even if the vaccine trials are successful, will the new vaccine cover all SARS-CoV-2 mutant strains, and give full immunity to everyone with no issues when translation to clinical practice? Can we produce enough, how much will it cost and who will pay (a particularly important issue in developing countries)? Can the new vaccine stop the threat of a second inevitable wave of coronavirus, or other pandemic viruses emerging to produce a similar situation in the future?

Gas therapy is a highly effective viral inactivation strategy. Carbon monoxide (CO) gas is very flammable and highly poisonous and referred to as the “Silent Killer,” because it binds to the parts of human blood that carry oxygen molecules, so it chemically blocks the body and organs from getting the needed oxygen. However, CO gas has also been shown to have antimicrobial and antiviral activities against infected cells (8), and two clinical trials (NCT02425579, NCT03799874) have demonstrated that the administration of low concentrations of CO is well-tolerated and safe in patients with sepsis-induced ARDS (9, 10). Similarly, while high concentrations of inhaled ozone (O₃) can damage the lungs, cause chest pain, coughing, shortness of breath, throat irritation, and worsen chronic respiratory diseases such as asthma as well as compromise the ability of the body to fight respiratory infections (11), ozone gas therapy has been demonstrated to inactivate airborne viruses (12) and could inactivate the SARS-CoV-2 virus through oxidizing the sulphydryl groups in cysteine of the virus-cell (13). There are also at least four ongoing clinical trials (NCT04290871 - NCT04306393 - NCT04305457 - NCT04290858) testing the use of inhaled nitric oxide (NO) gas for patients with COVID-19 (14), as increasing airway NO levels via gas inhalation or precursor molecules may improve oxygenation in COVID-19 subjects (15). As with the other gases, there is another side to NO, which can be harmful due to the formation of highly toxic and irritating nitrogen dioxide (NO₂) gas and methemoglobinemia (16).

THE HYPOTHESIS AND EVIDENCE

Carbon dioxide (CO₂) is a fundamental biological gas and has been used for medical purposes for over a century due to its unique properties (Figure 1). Carbon dioxide gas is natural, biocompatible, chemically stable, and safer than any other medical gases (NO, O₃, or CO). It has been shown to possess antioxidant and anti-inflammatory properties, to improve blood oxygenation and enhance oxygen delivery to organs, to protect and improve lung function, to function as a carrier, or enhancer gas for drug delivery by rapid and direct open airway inhalation with easy administration in home, GP, emergency unit, and
El-Betany et al. Carbon Dioxide Therapy as a Promising Anti-COVID-19

FIGURE 1 | Exceptional physical, biological, and medical properties of warmed humidified CO$_2$ gas.

ICU settings. These unique biological, physical, and medical properties of CO$_2$ make it a promising anti-COVID-19 therapy for mitigation and suppression of SARS-CoV-2 infection. Our hypothesis depends on inhaling precise doses of humidified and warmed CO$_2$ medical gas, either alone or as a composite carrier gas with other COVID-19 inhaler medications (bronchodilators, antivirals, antibiotics, or anti-cytokine agents), to disinfect the SARS-CoV-2 virus inside the infected human lung, as a preventative measure to stop coronavirus infection spreading, and to improve the treatment of mild, moderate, and severe COVID-19 symptoms. The following benefits and evidence of using medical carbon dioxide gas support the hypothesis.

**Universal Virucidal and Antimicrobial Activity**

Direct inactivation technologies have several limitations against the current virus. Moist, warm CO$_2$ gas could become a competitive disinfection technology. Carbon dioxide gas is an antiviral, antibacterial, and anti-infection agent effective not only on solid surfaces but also in aqueous solutions and water treatment settings (17). Heated, un-pressurized carbon dioxide bubbled through wastewater or aqueous media effectively destroys both waterborne bacteria and viruses (18). Moreover, supercritical CO$_2$ can in-activate and eliminate coronaviruses from an animal, human tissues and solid surfaces (19–21). Supercritical CO$_2$ offers a novel, user-friendly process to sterilize acellular tissue, such as lung matrices, for use in tissue and organ engineering (22). CO$_2$ can also enhance the effect of some other antibacterial agents, further improving the protection imparted (17). When breathing is impaired, CO$_2$-levels in the human body drop, which creates a favorable environment for bacterial growth and a higher risk of infection. Pure CO$_2$ significantly decreased the growth rate of most viruses and bacteria at body temperature; this inhibitory effect of CO$_2$ increased exponentially with time (23). This phenomenon could be attributed to unravels the secret of structure and function of the Endothelial Surface Layer (ESL) (24–27). As the venous ESL is probably comprised of nanobubbles of CO$_2$, generated from tissue metabolism, that presumably kills the viruses and bacteria exiting to the blood flow on the way to leaving via the lungs (27). Even though
the mechanism of inactivation of microorganisms by CO$_2$ is not yet resolved, there are a number of hypotheses that have been proposed to explain the unique disinfection action of CO$_2$ gas (28).

CO$_2$ gas is far superior to other similar gases, with much higher viral inactivation rates at lower temperatures (18–100°C) without the need for pressurization (18, 29). CO$_2$ interacts with water moisture to generate carbonic acid (pH 4.18), a reduced pH which could affect virus and microbial cell inactivation, as lipid membrane stability is disrupted and permeability to carbon dioxide increases (30, 31). However, a reduction in the pH of the medium is not sufficient to account for the antimicrobial action of CO$_2$, since it shows a specific inhibitory effect which is greater than that of the other acids used to lower the pH of media (hydrochloric acid, phosphoric acid, etc.) (32). These acids do not penetrate the microbial cells as easily as carbon dioxide (33). Cheng et al. believe that CO$_2$ molecules could enter virus capsids much more easily than H$^+$ and inactivate the virus (34). CO$_2$-protein binding could also damage the capsid, inactivating the virus. Both mechanisms may be active during dense phase carbon dioxide treatment (DPCD) which has also been shown to effectively inactivate viruses (31). The warm atmospheric pressure CO$_2$ gas during DPCD is suggested to have high viral inactivation effect by penetrating the virus capsid due to the high density of CO$_2$ with a high interfacial area (α) produced by the continuous CO$_2$-moist contact surface area (29). Following this; CO$_2$ can bind inside the capsid proteins through acid/base interactions (35), producing the high virus inactivation rates (18). Also, when compared with other gases (Air, O$_2$, N$_2$, and Argon), CO$_2$ gas has the highest inactivated viruses and bacteria rates in different NaCl solutions, even at ambient temperatures and normal atmospheric pressure (18). Recently, Edwards et al. demonstrate the effectiveness of aerosol administration of nasal saline comprising calcium and sodium salts diminishes exhaled particles and acts as a new natural defense against airborne pathogens in the human airways (36). Moreover, Zare and his teamwork report that spraying micron-sized water droplets can act as an effective disinfectant by causing inactivation of over 98% of the bacteria. They propose that the combined action of reactive oxygen species present in micron-size water droplets (but not in bulk water) along with the droplet surface charge is responsible for the observed bactericidal activity (37). The efficiency of CO$_2$ technology will require adjustment and control of the mechanical and dynamic behavior of moist CO$_2$ bubbles and properties such as temperature, flow and density rates, pressure, electrolyte pH, bubble size and thickness, surfaces area, and duration. All of these factors contribute to the observed fast microbial death (38).

**Safe and Tolerance for Human Clinical Trials and Treatment**

Carbon dioxide (CO$_2$) gas is natural, inexpensive, non-toxic at low concentrations (5,000 ppm), non-flammable, and readily available in high purity from a variety of sources. When CO$_2$ gas dissolves in water, it exists in chemical equilibrium with carbonic acid (pH = 4.18) which plays an essential role in the bicarbonate buffer system used to maintain acid-base homeostasis in the human body. The duration and concentration of carbon dioxide inhalation may be the key to the effective and protective role of CO$_2$ gas therapy. A recent study investigated that pre-treatment by CO$_2$ inhalation for 10 min, but not for 60 min, could improve lipopolysaccharide LPS-induced lung injury (39). A pre-clinical sheep model used perflubron combined with 12% CO$_2$ to open constricted airways treatment for severe acute asthma (40). As a reference, OSHA has set a CO$_2$ permissible exposure limit (PEL) of 5,000 ppm over 8 h and 30,000 ppm over 10 min. This compares favorably to CO gas at 50 ppm, NO gas at 25 ppm, and O$_3$ gas at 0.10 ppm for 8 h. Humans can tolerate up to 10% CO$_2$ before severe adverse effects are encountered (41) although CO$_2$ tolerance decreases with age ($p < 0.0001$) (42). Two clinical trials (NCT02616770 & NCT02334553) showed that perflubron carried in gas with ascending doses of carbon dioxide (4, 8, and 12% CO$_2$) administered to healthy subjects was safe and effective in subjects with mild asthma (43, 44), while other ongoing clinical trials (NCT03903913) are testing the safety and tolerability the same formulation in subjects with cystic fibrosis. Moreover, CO$_2$ concentrations of up to 35% have been applied in other clinical trial study used “CO$_2$ inhalation challenge model” through a protected inhalation system to measure the anxiolytic and panicolytic effects of new test compounds (45, 46).

**Suppressing Cytokine Storm**

Evidence is accumulating inferring that a subcategory of patients with acute COVID-19 might experience cytokine storm syndrome (47). CO$_2$ gas is one of the potential treatment strategies to dampen an overactive immune system and to quell a cytokine storm (48, 49). Many researchers have reported that the presence of CO$_2$ reduces the production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins 1 and 6 (IL-1 and IL-6, respectively), suggesting that the gas temporarily inhibits macrophage activity via a mechanism that could be associated with the reduction of the local or systemic pH (50–54). Carbon dioxide gas can also affect the production of pro-and anti-inflammatory cytokines in endotoxin-stimulated human whole blood cultures under hypercapnic, normocapnic, and hypocapnic conditions (55). In another study, CO$_2$ was shown to differentially affect the cytokine release of macrophage subpopulations exclusively via alteration of extracellular pH. Decreasing the extracellular pH to 6.5 mimicked the effects of CO$_2$ and a decrease to 5.5 suppressed IL-6 release in cell lines (53).

**Inhaled Carrier Gas Delivery System**

CO$_2$ gas has unique safety, chemical stability, biocompatibility, and properties as well as a higher density than oxygen, high solubility in tissue and blood and high tolerance in vascular system (56). CO$_2$ itself is a respiratory stimuli, enhances mucus clearance, and seems to be a bronchodilator by general induction of smooth muscle relaxation (57). Additionally, warmed and humidified CO$_2$ insufflation leads to an improved body core temperature (BCT) maintenance, a reduction of the inflammatory and cytokine responses (58, 59) and improved quality of postoperative course, compared
with standard insufflation (60, 61). Also, it can reduce intraoperative hypothermia, coagulation dysfunction, early postoperative cough pain, days to first flatus and solid food intake, and the length of hospital stays (62). In recent years, \text{CO}_2-based technologies have accordingly gained considerable interest in the pharmaceutical industry. \text{CO}_2 bubble-generating carrier systems can be used to locally accumulate a drug at diseased tissue, reducing side effects on the healthy tissue and improving their therapeutic effectiveness (63). \text{CO}_2 may also be used as an enhancer and carrier gas for delivery of effective medical agents into a surgical wound (64) or respiratory diseases such as severe acute asthma and cystic fibrosis (40, 43, 44).

**Clinical Usage and Medical Purposes**

Medical carbon dioxide has been used as a pure gas or in specialized mixtures with other gases in anesthesia, as an insufflation gas for minimally invasive surgery (65), and in carboxytherapy (66). It can be used in the expansion of blood vessels to increase carbon dioxide level after rapid breathing, and to stimulate breathing after a period of non-breathing (67). Transdermal carbon dioxide gas therapy is widespread and uses carbon dioxide gas at high humidity, to increase tissue blood flow. Tissue oxygenation generates new blood vessels, and well-oxygenated tissues improve the effectiveness of antibiotic therapy. This is complemented by the antioxidant effect of \text{CO}_2 itself, which reduces oxidative stress in open surgery (68), and improves wound healing (69).

**Benefits of Hypercapnic Therapy**

Hypercapnic therapy (elevated \text{CO}_2 levels) has beneficial effects on the physiology of the respiratory, cardiovascular, and nervous system. In human critical care, hypercapnic acidosis (HCA) is frequently acceptable and improves innate immune function, resistance to infection, and protects and improves lung functions in patients with advanced lung disease. However, all these benefits require careful consideration of when and for how long hypercapnia will be applied. Hypercapnic acidosis, but not buffered hypercapnia, was reported to reduce the severity of sepsis-induced lung injury (70). Recent studies suggest that HCA is protective in the earlier phases of bacterial pneumonia-induced sepsis, just as HCA is protective in preclinical models of early and prolonged systemic sepsis (71). Also, \text{CO}_2 gas in therapeutic hypercapnia and other forms of acidosis techniques is an excellent antioxidant and anti-inflammatory agent (72). Hypercapnic acidosis was associated with benefits on lung and distant organs in several disease models, apart from the reduction of ventilation parameters.

---

**FIGURE 2** | Suggested protocol for early and daily inhaling \text{CO}_2 gas (2–4%) itself or composite with other COVID-19 inhaler medications could help in precaution and protection strategy to coexistence and adaptation with COVID-19 pandemic.

**FIGURE 3** | Suggested protocol for early inhaling \text{CO}_2 gas (4–14%) itself or composite with other COVID-19 inhaler medications could save lives by disinfection and improve mild and moderate COVID-19 patient treatment.
such as ventilator-induced lung injury (73), acute respiratory distress syndrome (ARDS) (74), ischemia-reperfusion injury (75) and sepsis (76), therapeutic hypercapnia through inspired carbon dioxide attenuated lung injury, as measured by gas exchange, reduced cytokine release, lung oedema formation, and histological lung injury. Hypercapnic acidosis improves ventilation-perfusion matching that also improves gas exchange (77), prevents oedema formation (78), clears the alveolar fluid in pulmonary oedema (79), maintains the integrity of the blood-brain-barrier and reduces neurologic deficits after trauma (80). HCA also reduces the oxidative stress that contributes to pathologic thick mucus gel formation in the lung (81, 82). It is hoped that hypercapnia therapy may offer real benefits, but well-planned and executed clinical studies will be required.

Recent COVID-19 Contradictory Studies
The partial pressure of CO\(_2\) in the atmosphere varies between 0.03 and 0.06% (83) but forms a high proportion (12.5–13.5%) with water vapor (1.3%) of the mainstream cigarette smoke (84). Recent studies have discovered the unusually low prevalence of current smoking was observed among hospitalized COVID-19 patients compared to the expected prevalence based on smoking prevalence in China. This preliminary analysis does not support the argument that current smoking is a risk factor for hospitalization for COVID-19, and might even suggest a protective role (85). Other cross-sectional studies in both COVID-19 out- and in-patients strongly suggests that daily smokers have a very much lower probability of developing symptomatic or severe SARS-CoV-2 infection as compared to the general population (86, 87). However, on the other hand, researchers at Baylor College of Medicine, the University of South Carolina and other institutions have identified tobacco smoking as a potential risk factor for the COVID-19 virus, due to increasing the expression of ACE2, the receptor of SARS-CoV-2, in the lungs (88, 89). These two contradictory studies support our hypothesis of moist warm CO\(_2\) gas resulted from cigarettes smoking could kill the SARS-CoV-2 viruses inside the infected lungs of smoker patients, and that leads to decreasing the infected COVID-19 patient from the smoker, not the nicotine or other outcomes of mainstream cigarette.

TESTING THE HYPOTHESIS (A): PRECLINICAL STUDY AND INACTIVATION MECHANISMS

Herein, we recommend preclinical studies to optimize the relation between disinfection efficacy and toxicity level of warm humidified CO\(_2\) gas while considering other related parameters to discover the possible mechanism of action of disinfection by CO\(_2\) gas. The temperature inside healthy lungs is around 37°C, the pH is between 7.38 and 7.42, and the relative humidity ranges from 30 to 70%. It is essential to keep humidity stable as too high humidity provides optimal conditions for microbial growth, and low humidity and dry air can dry mucous membranes and make them more susceptible to infection (90). The SARS-CoV-2 virus is highly stable at 4°C, but it is very sensitive to heat. It is remarkably stable in a wide range of pH values (pH 3–10) at room temperature (22°C) (91, 92). However, the stability of SARS-CoV-2 under different environmental conditions of temperature, pressure, relative humidity, and pH with biological tissue and barriers require further investigation.

TESTING THE HYPOTHESIS (B): CLINICAL EVALUATION AND IMPLICATIONS

Whilst the properties and clinical applications of CO\(_2\) have been known for many decades; parameters must be systematically studied before it can be used in a new clinical setting.

(I) Healthy, Non-symptomatic, Mild, and Moderate Care Levels
Optimizing the balance between disinfection efficacy and toxicity of humidified warmed CO\(_2\) gas considering other parameters (temperature, relative humidity, pressure flow and density rates, electrolyte pH, bubble size and thickness, surfaces area, and duration) will be key. Different regimes will be needed to protect healthy and non-symptomatic patients and improve the condition of those suffering mild and moderate COVID-19 symptoms. Multiple-ascending dose studies in which subjects with mild to moderate COVID-19 will be enrolled [CO\(_2\) max 14%, tolerance decreases with age (p < 0.0001)] (42). The suggested study could consist of a screening period, a run-in, dosing and evaluation periods, and a follow-up period. The dosing and evaluation period of the study could divide into three connected components. First, a dose-escalation study—This segment of the treatment period is designed to assess the safety and tolerability of escalating doses of medical CO\(_2\) gas (2–4%) in a healthy volunteer (Figure 2), and (4, 8, 12, and 14%) in those with mild-moderate COVID-19 symptoms (Figure 3). Second, a daily dosing study - This segment of the treatment period is designed to assess the short term (5 days) safety and tolerability of 1–2 times daily administrations of a fixed dose of medical CO\(_2\) gas in healthy volunteers, and 2–3 times daily administration of a fixed dose of medical CO\(_2\) gas in patients with mild-moderate COVID-19. Third, a drug delivery study - This segment of the treatment period is designed to assess the safety, efficacy, enhancing, and tolerability of humidified warmed CO\(_2\) gas (2–14%) composed with other inhaled medication such as an antiviral (Remdesivir or IFN-β SNG001), short-acting bronchodilator, antibiotic, anti-inflammation. The recommended clinical trial study may well-include placebo-control, humidified warmed CO\(_2\) gas (2–14%), and humidified warmed CO\(_2\) gas (2–14%) composed with other inhaled medication. Administration can be achieved through using simple comprised cartridge MDI puff, portable nebulizer, or circularize II high-efficiency aerosol drug delivery system nebulizer in a negative pressure environment. Direct air/oxygen inhalation for a few minutes can be used to recover patients to
baseline carbon dioxide levels. A safety monitoring committee must also review the results from each cohort before deciding continuation of the study at the next prescribed dose level, based on consideration of the clinical significance of safety and tolerability parameters.

(II) Severe Care Level
The damage mechanisms of SARS-CoV-2 are still unclear, with severe COVID-19 cases are complicated by high mortality rates due to compromised immune function and a high probability of antibiotic-resistant secondary infections. Most severe COVID-19 cases are associated with respiratory failure, with many already suffering from internal high hypercapnia acidosis (with humidity levels near 100%) that disrupt not only cardiac and neurological functions but also immune system function by suppressing both innate and adaptive immune responses to viral and bacterial proliferation and infection (54, 93–96). This dysfunction of the immune system with increasing SARS-CoV-2 infection can lead to an overreaction of the immune system (cytokine storm), during which white blood cells are misdirected to attack and inflame even healthy tissue, leading to failure of the lungs, heart, liver, intestines, kidneys, and genitals (Multiple Organ Dysfunction Syndrome, MODS). This may, in turn, lead to the lungs shutting down (Acute Respiratory Distress Syndrome, ARDS), which makes absorption of oxygen difficult. Most deaths due to COVID-19 are due to respiratory failure. To save the lives of severely affected patients if they are already connected to life support and artificial blood purification through mechanical means, and a controlled gas mixture consisting of 25% CO₂ and 75% O₂ is delivered through a protected inhalation system while monitoring a wide range of physiological parameters, and administering supportive organ function treatments.

CONCLUSION AND EXPECTING OUTCOMES
There is an urgent global need for a universal vaccine to cover all SARS-CoV-2 mutant strains to stop the threat of an inevitable second wave of coronavirus. Currently, there are hundreds of clinical trials, but not yet any approved antiviral drugs specific for the treatment of COVID-19. The physical, biological, and medical properties of CO₂ gas suggest that humidified warmed CO₂ gas possesses multiple bioactivities and offer a new concept to SARS-CoV-2 viral disinfection and COVID-19 treatment. This inexpensive and broadly applicable therapy could lead to a massive reduction in the global number of infected, especially when used as a carrier for delivery of other inhaled drugs and creates new possibilities for mitigation and suppression of any COVID-19 second wave, or indeed any new future respiratory viral pandemic. In the future, more bioactive properties of CO₂ could be identified, and their mechanisms of action investigated. We believe well-designed clinical trials of CO₂ and its various bioactive properties are warranted to examine its efficacy against these diseases in human beings. It is hoped that
this hypothesis will serve as a stimulus for further investigation into this issue.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

All authors contributed to the article and approved the submitted version. AE-B: conceptualization, methodology, writing—original draft, and writing—review and editing. EB: writing—review and editing. MG and KH: conceptualization and writing—review and editing.

REFERENCES

1. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of covid-19 in the young. N Engl J Med. (2020) 382:e60. doi: 10.1056/NEJMc2009787

2. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. (2020) 26:681–7. doi: 10.1038/s41591-020-0868-6

3. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature. (2020) 582:557–60. doi: 10.1038/s41586-020-2271-3

4. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. (2020) 7:nsw036. doi: 10.1093/nsr/nsw036

5. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. (2020) 27:1451–4. doi: 10.1038/s44180-020-0530-3

6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7

7. Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. (2020) 580:576–7. doi: 10.1038/s41586-020-01221-y

8. Ma Z, Pu F, Zhang X, Yan Y, Zhao L, Zhang A, et al. Carbon monoxide and biliverdin suppress bovine viral diarrhea virus replication. J Gen Virol. (2017) 98:2982–92. doi: 10.1099/jgv.0.009955

9. Fredenburgh LE, Kraft BD, Hess DR, Harris RS, Wolf MA, Suliman HB, et al. Effects of inhaled CO administration on acute lung injury in baboons with pneumococcal pneumonia. Am J Physiol Lung Cell Mol Physiol. (2015) 309:L834–46. doi: 10.1152/ajplung.00240.2015

10. Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, et al. A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight. (2018) 3:e124039. doi: 10.1172/jci.insight.124039

11. Barrese E, Giofrè A, Scarpelli M, Turbante D, Trovato R, Iavicoli S. Indoor pollution in work office: VOCs, formaldehyde and ozone by printer. J Gen Virol. (2020) 101:2729–39. doi: 10.1099/jgv.0.009381-C

12. Dubuis ME, Dumont-Leblond N, Laliberté C, Veillette M, Turgeon N, et al. Ozone efficacy for the control of airborne viruses: bacteriophage and norovirus models. PLoS ONE. (2020) 15:e0231164. doi: 10.1371/journal.pone.0231164

13. Rowen RJ, Robins H. A plausible “Penny” costing effective treatment for corona virus ozone therapy. J Infect Dis Epidemiol. (2020) 4:113. doi: 10.23937/2474-3658/1510113

14. Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med. (2020) 8:433–4. doi: 10.1016/S2213-2600(20)30127-2

15. Martel J, Ko YF, Young JD, Ojcius DM. Could nasal nitric oxide help to mitigate the severity of COVID-19? Microb Infect. (2020) 22:168–71. doi: 10.1016/j.micinf.2020.05.002

16. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. (2004) 109:3106–11. doi: 10.1161/01.CIR.0000134595.80170.62

17. Martirosyan V, Hovhanyan K, Ayrapetyan S. Carbon dioxide as a microbial toxicity enhancer of some antibacterial agents: a new potential water purification tool. ISRN Biophys. (2012) 2012:906761. doi: 10.5402/2012/906761

18. Garrido Sanchis A, Pashley R, Ninham B. Virus and bacteria inactivation by CO2 bubbles in solution. NPJ Clean Water. (2019) 2:5. doi: 10.1038/s41553-018-0027-5

19. Fages, Jacques, Patrick Frayssinet, and Gilbert Bonel. “Uses for a current of supercritical carbon dioxide as an antiviral agent.” U.S. Patent No. 5,732,012. 3 Mar. 1998. Washington, DC: U.S. Patent and Trademark Office.

20. Fages J, Frayssinet P, Bonel G. Antiviral treatment of collagenous material for use as prostheses and grafts-by treating with supercritical carbon dioxide, hydrogen peroxide, sodium hydroxide and ethanol, preventing viral contamination from e.g. Hepatitis C. Patent EP748632-A1; FR2735372-A1; US57230212-A; EP748632-B1; DE69619893-E; ES2174035-T3. Bioland Sarl; Depuy Bioland (1997).

21. Qiu Y, Lin G, Zhang M, Chen Q. Method for removing the activity of contamination from e.g. Hepatitis C. Patent CN1721526-A; CN1318581-C. Nanwei Ind Co Ltd. (2006).

22. Balestrini JL, Liu A, Gard AL, Huie J, Blatt KMS, Schwan J, et al. Sterilization of lung matrices by supercritical carbon dioxide. Tissue Eng C Methods. (2016) 22:260–9. doi: 10.1089/tenc.2015.0449

23. Persson M, Svenarud P, Frod JI, Van Der Linden J. Carbon dioxide inhibits the growth rate of Staphylococcus aureus at body temperature. Surg Endosc Other Interv Tech. (2005) 19:91–4. doi: 10.1007/s00464-003-9334-2

24. Rizzo AN, Dudek SM. Endothelial glycolcayl repair: building a wall to protect the lung during surgery. Am J Respir Cell Mol Biol. (2017) 56:867–88. doi: 10.1165/rcmb.2017-0065ED

25. Curry FE. The molecular structure of the endothelial glycolcayl layer (EGL) and surface layers (ESL) modulation of transvascular exchange. Adv Exp Med Biol. (2010) 633:29–49. doi: 10.1007/978-3-90264-5_42

26. Sieve I, Münster-Kühnel AK, Häfiker-Kleiner D. Regulation and function of endothelial glycolcayl layer in vascular diseases. Vasc Pharmacol. (2018) 100:26–33. doi: 10.1016/j.vph.2017.09.002

27. Reines BP, Ninham BW. Structure and function of the endothelial surface layer: unraveling the nanoarchitecture of biological surfaces. Q Rev Biophys. (2019) 52:e13. doi: 10.1017/S0033585319000118

28. Isenschmid A, Marison I, Von Stockar U. The influence of pressure and temperature of compressed CO2 on the survival of yeast cells. J Biotechnol. (1995) 39:229–37. doi: 10.1016/0168-1656(95)0018-L

ACKNOWLEDGMENTS

We thank our colleagues and the members of RIS at Cardiff University for comments on the manuscript, R. Mart, R. Weiser, A. Staphnill, R. Turner, M. Morgan, and C. Butler. Also, we thank The College of Biomedical and Life Sciences (BLS) at Cardiff University for financial support through the Wellcome Trust Institutional Strategic Support Fund (ISSF). This manuscript has been released as a pre-print at OSF Preprints (98).
32. Becker Z. A comparison between the action of carbonic acid and other acids.

33. Debs-Louka E, Louka N, Abraham G, Chabot V, Allaf K. Effect of compressed
Dense Phase Carbon Dioxide: Food

34. Cundari TR, Wilson AK, Drummond ML, Gonzalez HE, Jorgensen KR, Payne
10:40. doi: 10.1186/s13578-020-00494-4

35. Edwards D, Hickey A, Batycky R, Griel L, Lipp M, Dehaan W, et al.

36. Dulay MT, Lee JK, Mody AC, Narasimhan R, Monack DM, Zare RN.

37. El-Mays T, Choudhury P, Leigh R, Koumoundouros E, Velden J, et al. A phase I, placebo-controlled, randomized, double-blind, single
crossover, single-dose clinical trial of a new class of bronchodilator for acute
impairment after open heart surgery. Ann Thoracic Surg. (2008)
86:130–40. doi: 10.1016/j.athoracsur.2007.08.047

38. Schlottecker H, Schaeffer R, Dow WA, Diemunsch P. Cold nebulization used
to prevent heat loss during laparoscopic surgery: an experimental study in
pigs. Surg Endosc. (2008) 22:2616–20. doi: 10.1007/s00464-008-9861-z

39. Noll E, Schaeffer R, Joshi G, Diemunsch S, Koessler S, Diemunsch P. Heat
loss during carbon dioxide insufflation: comparison of a nebulization-based
humidification device with a humidification and heating system. Surg Endosc.
(2012) 26:3622–5. doi: 10.1007/s00464-012-2385-2

40. Jiang R, Sun Y, Wang H, Liang M, Xie X. Effect of different carbon
dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: a randomized controlled trial. Medicine. (2019)
98:e17520. doi: 10.1097/MD.0000000000017520

41. Lin HM, Yang Z, Chen LF. Inactivation of saccharomyces cerevisiae by
hyperinflammatory response in septic animals during laparotomy? Surg
Res Pract. (2020) 2020:5738236. doi: 10.1155/2020/5738236

42. Gill M, Natoli MJ, Vacciano C, MacLeod DB, Ikeda K, Qin M, et al. Effects of elevated oxygen and carbon dioxide partial pressures on
respiratory function and cognitive performance. J Appl Physiol. (2014)
117:406–12. doi: 10.1152/japplphysiol.00995.2013

43. Winkler JL, Jeronimo J, Singleton J, Janmohamed A, Santos C. Performance
carrier gas for drug delivery into open wounds. Med Hypotheses. (2009)
72:121–4. doi: 10.1016/j.mehy.2008.08.026

44. Winkle JK, Jeronimo J, Singleton J, Janmohamed A, Santos C. Performance
of cryotherapy devices using nitrous oxide and carbon dioxide. Int J Gynecol
Obstetr. (2010) 111:73–77. doi: 10.1016/j.ijgo.2010.04.032

45. Verrier N, Fournier C, Fournel T. 3D tracking the brownian motion of
colloidal particles using digital holographic microscopy and joint
reconstruction. Appl Opt. (2015) 54:4996–5002. doi: 10.1364/AO.54.049996

46. Yu T, Cheng Y, Wang X, Tu B, Cheng N, Gong J, et al. Gases for establishing
pneumoperitoneum during laparoscopic abdominal surgery. Cochrane Database Syst Rev. (2017)
6:CD009569. doi: 10.1002/14651838.CD009569.pub3
68. Tsuchiya M, Sato EF, Inoue M, Asada A. CO2 El-Betany et al. Carbon Dioxide Therapy as a Promising Anti-COVID-19
71. Curley G, Contreras M, Nichol A, Higgins B, Laffey JG. Higgins BD, Costello J, Contreras M, Hassett P, O'Toole D, Laffey JG.
73. Peltekova V, Engelberts D, Otulakowski G, Uematsu S, Post M, Kavanagh BP.
84. Guais A, Brand G, Jacquot L, Karrer M, Dukan S, Grévillot G, et al.
4. doi: 10.3334/CDIAC/ATG.NDP001
Keeling CD, Whorf TP. In Vivo.
Yang WC, Wang Q, Chi LT, Wang YZ, Cao HL, Li WZ. Therapeutic hypercapnia reduces blood–brain barrier damage possibly via protein kinase Cε in rats with lateral fluid percussion injury. J Neuroinflammation. (2019) 16:36. doi: 10.1189/jlb.71.4.603
Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen HL, Chan MCW, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. (2020) 1:e10. doi: 10.1016/S2666-5247(20)30003-3
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. (2020) 382:1564–7. doi: 10.1056/NEJMoa2004973
Cookley R, Taggart C, Greene C, McElvaney N, O’Neill S. Ambient pCO2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J Leukocyte Biol. (2002) 71:603–10. doi: 10.1189/jlb.71.4.603
Vadáš I, Hubmayr RD, Nin N, Sporn PH, Sznaider JJ. Hypercapnia: a non-permissive environment for the lung. Am J Respir Cell Mol Biol. (2012) 46:417–21. doi: 10.1165/rcell.2011-0395PS
Pugin J, Dunn-Siegist I, Dufour J, Tissieres P, Charles PE, Comte R. Cyclic stretch of human lung cells induces an acidification and promotes bacterial growth. Am J Respir Crit Care Med. (2008) 38:362–70. doi: 10.1165/rcrm.2007-0114OC
Helenius IT, Krupinski T, Turnbull DW, Gruenbaum Y, Silverman N, Johnson EA, et al. Elevated CO2 suppresses specific drosophila innate immune responses and resistance to bacterial infection. Proc Natl Acad Sci USA. (2009) 106:18710–15. doi: 10.1073/pnas.0905925106
Xie P, Ma W, Tang H, Liu D. Severe COVID-19: a review of recent progress with a look toward the future. Front Public Health. (2020) 8:189. doi: 10.3389/fpubh.2020.00189
El-Betany A, Behiry E, Gumbleton M, Harding K. Humidified warmed CO2 treatment therapy strategies can save lives with mitigation and suppression of SARS-CoV-2 infection: an evidence review. OSF Preprints. [Preprint]. doi: 10.32199/osf.io/7qj2q
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2020 El-Betany, Behiry, Gumbleton and Harding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.